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ABSTRACT
During pregnancy and lactation, the maternal skeleton undergoes significant bone loss through increased resorption to provide
the necessary calcium supply to the developing fetus and suckling neonate. This period of skeletal vulnerability has not been
clearly associated with increased maternal fracture risk, but these physiological conditions can exacerbate an underlying meta-
bolic bone condition like osteogenesis imperfecta. Although bisphosphonates (BPs) are commonly used in postmenopausal
women, there are cases where premenopausal women taking BPs become pregnant. Given BPs’ long half‐life, there is a need to
establish how BPs affect the maternal skeleton during periods of demanding metabolic bone changes that are critical for the
skeletal development of their offspring. In the present study, pamidronate‐ (PAM‐) amplified pregnancy‐induced bone mass gains
and lactation‐induced bone loss were prevented. This preservation of bone mass was less robust when PAM was administered at
late stages of lactation compared with early pregnancy and first day of lactation. Pregnancy‐induced osteocyte osteolysis was also
observed and was unaffected with PAM treatment. No negative skeletal effects were observed in offspring from PAM‐treated
dams despite lactation‐induced bone loss prevention. These findings provide important insight into (1) a treatment window for
when PAM is most effective in preserving maternal bone mass, and (2) the maternal changes in bone metabolism that maintain
calcium homeostasis crucial for fetal and neonatal bone development. © 2019 American Society for Bone and Mineral Research.
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Introduction
Pregnancy and lactation are known as periods of significantmaternal bone loss based on changes in calcium homeo-
stasis required for fetal bone mineralization and breast milk
production. Because the decrease of maternal bone has been
shown to be transitory, this reproductive period has not been
clearly associated with osteoporosis or increased maternal
fracture risk.(1) However, it remains uncertain if these physio-
logic conditions define a period of vulnerability for the
maternal skeleton associated with a rare underlying metabolic
bone disorder such as osteogenesis imperfecta (OI).
Limited information on the maternal skeletal outcome following
pregnancy and lactation in women with OI is known(2–4); however,
fractures and other complications have been reported.(5–8)
Currently, bisphosphonates (BPs) are the most widely prescribed
antiresorptive for the treatment of metabolic bone diseases
associated with excessive bone resorption.(9,10) Through their high
affinity for calcium ions, these synthetic analogues bind to
hydroxyapatite crystals within the bone matrix to mediate an
inhibitory effect on active osteoclasts to decrease bone turnover
and increase bone mineral density.(11–17) Although the majority of
patients treated with BPs are postmenopausal, children and
women of childbearing age are increasingly being prescribed these
treatments.(18–20) Because BPs can remain sequestered within the
bone matrix until they are taken up by osteoclasts, there is rising
concern that fetal exposure could occur in cases where the mother
has been subjected to BP treatment prior to conception. Addi-
tionally, it has been shown that other medications and drugs have
the potential to pass from the mother's bloodstream into breast
milk and reach the nursing infant.(21–24) Although clinical case
studies have reported the benefits of BPs for the treatment of
pregnancy and lactation‐associated osteoporosis (PLO), glucocorti-
coid‐induced osteoporosis, hypercalcemia, and other complications
during pregnancy and lactation,(19,25–28) data on the effects of
BP exposure of the mother and possibly the offspring during
pregnancy or lactation remains limited.
Currently, BPs have been classified by the US Food and Drug
Administration as holding a category C pregnancy risk because
animal reproduction studies have shown adverse effects, and no
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adequate and well‐controlled studies in humans have been re-
ported.(29) Our current understanding of BP effects during preg-
nancy rely heavily on animal studies, which have shown that these
drugs are capable of crossing the placenta, thus putting the fetus at
risk for exposure in utero.(30–33) Although these animal studies
showed that BP exposure led to low birth weight, under-
development, and skeletal retardation, toxic levels up to 10 times
the therapeutic dosage used clinically were administered to assess
their safety during pregnancy and lactation. Two toxicity animal
studies have also explored the effects of BPs during lactation,
where severe and mild hypocalcemia was observed caused by a
disruption in maternal calcium metabolism.(34–37) Of the case
studies that are available, neither mother nor infant demonstrated
serious adverse effects; however, a few studies did report low birth
weight, low gestational age, and transient asymptomatic hypo-
calcemia in the offspring.(38–46)
Recommendations regarding the use of BPs during lactation
are often conflicting because it is not entirely known howmuch of
a given drug passes the placenta or diffuses into breast milk;
studies do not agree on a common conclusion. Thus, there re-
mains a need for developing systematic studies on the effects of
BPs when treating the maternal skeleton during a period of de-
manding metabolic bone changes that are critical for the skeletal
development of offspring. In the present study, we sought to
determine a therapeutic window for when pamidronate (PAM) is
most potent on the maternal skeleton and how exposure affects
fetal and neonatal development. We hypothesized that PAM re-
sorption effects on the maternal skeleton will be highly de-
pendent on the time of administration because bone metabolism
is constantly changing throughout pregnancy and lactation. Off-
spring are at risk of PAM exposure if BPs cross the placenta or
diffuse into breast milk, even if the mother has stopped treatment
prior to conception, because of BPs long‐half‐life and their release
into the bloodstream following maternal bone resorption. Addi-
tionally, because the maternal skeleton serves as a calcium res-
ervoir to maintain calcium homeostasis during ossification and
mineralization of their offspring, BPs have the potential to inter-
fere with maintaining this balance and indirectly affect fetal/ne-
onatal bone development. To explore these questions, we tested
BP effects using a single injection of PAM at different stages of
pregnancy and lactation in Brtl/+ dams harboring an OI‐causing
defect. This knock‐in mouse model reproduces the phenotype of
moderately severe type IV OI(47–49) and has been used to explore
therapeutic efficacy of antiresorptive and anabolic interventions in
growing and aged mice.(50–55) Additionally, we genotyped and
sexed offspring from treated and untreated Brtl/+ dams to ex-
plore the sequela of events resulting from PAM exposure on the
maternal skeleton. In the present study, a temporal effect on the
preservation of bone mass was observed when PAM was ad-
ministered at different stages of pregnancy and lactation. This
protective effect was more modest when given during pregnancy
(E15) and ceased to exist when PAM was given during the late
stages of lactation. Despite preventing lactation‐induced bone
loss, no adverse effect on fetal and neonatal bone development
was found, suggesting additional sources of calcium are capable
of responding to the demands placed on the maternal skeletal.
Materials and Methods
Experimental design
Brtl/+mice with a mixed background of SV129/CD‐1/C57BL/6 S
were derived from heterozygous Brtl/+ and WT parental
strains.(47) To identify temporal maternal skeletal changes during
pregnancy and lactation in OI and how these skeletal changes are
affected with PAM, female Brtl/+ (n= 10/group) mice between 12
and 18 weeks of age were randomly assigned to receive a single
tail vein injection of either PAM (3mg/kg) or vehicle (PBS) during
one of five timepoints (prior to conception [PC], gestation day 15
[E15], lactation day 1 [D1], lactation day 10 [D10], or lactation day
15 [D15]). This single PAM dose represents a standard clinical
dosage that has been used during pregnancy.(19) For successful
timed pregnancies, female Brtl/+were mated with experienced
male WT breeders and pregnancy was assessed by examining for
a vaginal plug. Pregnant mice were caged individually and were
continued on standard chow diet (5L0D; PicoLab, St. Louis, MO,
USA) throughout pregnancy and lactation. Standard chow
contained a calcium concentration of 6.6% and 4.6 IU/gm of
vitamin D. To isolate the effects of pregnancy, mothers, along with
their litter, were euthanized at birth. To assess both pregnancy
and lactation effects, mother and litter were euthanized at
weaning (D21). As a control, age‐matched virgin female Brtl/
+mice (n= 10) were assessed to establish a skeletal baseline
uninfluenced by pregnancy and lactation. A summary of the ex-
perimental design for maternal and neonatal assessment of
skeletal changes during pregnancy and lactation under the in-
fluence of PAM is shown in Fig. 1. All protocols and procedures
were approved by the University of Michigan’s Committee on Use
and Care of Animals.
Nontherapeutic fluorescent bisphosphonate probe
A single injection of commercially available far‐red fluorescent
pamidronate (FRFP) Osteosense‐680EX (Perkin Elmer, Bedford,
MA, USA) was administered in Brtl/+ pregnant dams (gestation
day 19) to assess if BPs crossed the placenta. The administered
dosage was 2 nmols of FRFP buffered in PBS in a tail vein in-
jection volume of 150 μL. For comparison, this nontherapeutic
fluorescent bisphosphonate probe is approximately 80 nmol/kg,
which is significantly lower than our 3mg/kg PAM therapeutic
dose, which is approximately 10,750 nmol/kg. Controls received
a 150‐µL tail‐vein injection of PBS.
Far‐red fluorescent pamidronate imaging
To assess if BPs crossed the placenta, we looked for FRFP in-
corporation into the fetal skeleton. Pregnant Brtl/+ dams (ges-
tation day 19) were euthanized within 24 hours of FRFP injection.
Embryos were fresh‐frozen in chilled isopentane at −70°C in O.C.T.
compound embedding medium (Fisher Chemical Co., Santa Clara,
CA, USA) and stored at –80°C. Frozen samples were sectioned to a
thickness of 10 µm using the Kawamoto film technique(56) and a
Leica CM3050S cryostat (Leica Microsystems, Wetzlar, Germany).
Fluorescent images from tissue sections were acquired with a
20× dry objective using a Zeiss Axiovert 200M inverted micro-
scope (Carl Zeiss, Oberkochen, Germany).
Micro‐computed tomography
To analyze maternal and neonatal bone morphological
changes after pregnancy and lactation, excised L3 vertebrae
and right femora were first fixed in 10% neutral buffered for-
malin. Following fixation, both vertebrae and femurs were
scanned in water using high‐resolution μCT (Brucker Skyscan
1176; Brucker, Kontich, Belgium). Image acquisition was per-
formed at 50 kV and 800 μA with a 0.3‐degree rotation step and
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a 0.25‐mm aluminum filter for filtration of beam‐hardening
artifacts. Manufacturer‐provided hydroxyapatite phantoms
were scanned with the same parameters to calibrate and
compute volumetric BMD. Individual 2D cross‐sectional images
were reconstructed into 3D volumes with 9‐μm isotropic voxel
size using NRecon software (version 1.6.5.8; Bruker).
Two volumes of interest were established to analyze the
effect of PAM during pregnancy and lactation on the femur. A
2‐mm (maternal) and 1‐mm (neonatal) volume of interest (VOI)
were centered midway between the lateral third trochanter
and the distal femoral growth plate for cortical analysis and
segmented using a user‐defined global threshold derived from
calculating the average thresholds over a range of samples. For
trabecular analysis, a VOI spanning 15% of total femoral length
for maternal bone and 7% for neonatal bone was placed at the
metaphysis just proximal to the distal growth plate. Manual
contours were used to isolate the trabecular compartment;
further segmentation was performed using an automatic
adaptive thresholding algorithm.
For vertebral analysis, a VOI was placed between the cranial
and caudal endplates of maternal and neonatal L3 vertebrae.
Vertebral cortical and trabecular bone were separated through
manual contouring to denote the outer and inner boundaries
of the cortex and segmented with automatic adaptive thresh-
olding. The areas of interest were analyzed with CTAn software
(version 1.15.4.0; Bruker). The bone architecture parameters
analyzed included trabecular number (TbN), trabecular thick-
ness (TbTh), bone volume fraction (BV/TV), cortical thickness
(CTh), and bone mineral density (BMD). Representative femoral
and vertebral isosurfaces were obtained using commercially
available software (MicroView Advanced Bone Analysis Appli-
cation; GE Healthcare Pre‐Clinical Imaging, London, ON,
Canada).
Backscatter scanning electron microscopy
Previous studies have shown that osteocyte osteolysis plays an
important role during lactation.(57–60) To assess physiologic os-
teocytic remodeling in our study, the lacunar area was measured
on maternal cortical bone of right femora. Following µCT
imaging, maternal right femora were embedded without de-
calcification in methyl methacrylate and sectioned transversely
below the lateral third trochanter using an Isomet low‐speed
diamond saw (Buehler Ltd., Lake Bluff, NY). Two‐hundred–micron
sections were then polished and mounted on aluminum stubs
using an alcoholic colloidal graphite solution. Images of osteo-
cyte lacunae on the sectioned bone surface were acquired with a
scanning electron microscope equipped with a backscattered
electron detector (BSEM, TESCAN MIRA3 FEG‐SEM, TESCAN, Brno,
Czechia) at 30‐kV accelerating voltage, 300‐pA current, and
10‐mm working distance. Acquired high‐contrast images were
then converted into binary mask using ImageJ software (NIH,
Bethesda, MD, USA; https://imagej.nih.gov/ij/), and areas were
measured for all lacunae in the anterior, posterior, lateral, and
medial 0.33‐mm× 0.33‐mm quadrants of the femoral cortex. No
regional differences were observed, so all quadrants were
combined to represent an overall average.
Biomechanical testing
To assess the mechanical effects during pregnancy and lacta-
tion and the influence of PAM during these events, maternal L5
vertebra and left femora were loaded to failure in compression
and four‐point bending, respectively, using an MTS 858 Mini‐
Bionix Servo‐Hydraulic Testing System (MTS Systems Corp.,
Eden Prairie, MN, USA). All specimens were kept hydrated in
lactated ringer's solution (LRS) prior to mechanical testing. The
vertebral body was vertically aligned along its loading axis with
an alignment pin (attached to lower platen and extending
through the spinal column) and compressed to failure at a
displacement rate of 0.05mm/second. For four‐point bending,
the posterior surface of the femur was oriented in tension and
the middiaphysis was loaded to failure at a displacement rate
of 0.5 mm/second. Force and vertical displacements were
continuously recorded throughout each test by a 50‐lb load cell
(Sensotec, Columbus, OH, USA) and an external linear variable
differential transducer (LVDT; Lucas Schavitts, Hampton, VA,
USA), respectively. A custom‐developed LABVIEW program was
used to calculate the mechanical properties for both tissues.
Tartrate‐resistant acid phosphatase staining
Qualitatively, histochemical staining of the biochemical marker
tartrate‐resistant acidic phosphatase (TRAP) has been used to
identify osteoclasts. To assess TRAP in maternal and neonatal
trabecular bone, right proximal tibias were fixed (4% neutral
buffered formalin), decalcified (10% EDTA for 21 days), and
embedded in paraffin. Ribbons of serial sections (6 μm) were
cut with an automated Leica RM2255 (Leica, Wetzlar, Germany)
rotary microtome and disposable low‐profile stainless steel
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Fig. 1. Assessing pamidronate (PAM) effects at different stages of pregnancy and lactation in the maternal skeleton. Single injection of PAM
treatment or PBS was administered during pregnancy and lactation in Brtl/+ dams. Virgin controls were used to establish a skeletal baseline
uninfluenced by these reproductive periods.
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blades (Accu‐Edge, 4689; Sakura Finetek USA Inc, Torrance, CA).
Collected sections were mounted on Superfrost/Plus glass
slides (Fisher, Pittsburgh, PA, USA) and left to dry overnight on
a 40°C slide warmer. Staining for TRAP was carried out with an
Acid Phosphatase, Leukocyte (TRAP) Kit (Sigma‐Aldrich, St.
Louis, MO, USA) according to the manufacturer’s instructions.
Images were acquired using an upright microscope (Nikon
Eclipse Ni‐U; Nikon, Inc., Melville, NY, USA) associated with a DS‐
Fi2 digital camera, NIS BR software (Nikon France, Champigny‐
sur‐Marne, France) and a 20× dry objective. Histomorphometric
analysis of maternal osteoclasts was acquired from two ROIs;
the first was placed proximal to the growth plate at a span of
5 mm; the second spanned 12.5 mm placed 5mm distal to the
growth plate. For neonates, because of the high mineralized
bone concentrated below the growth plate, a single 17.5 mm
ROI was placed 12.5 mm distal the growth plate. In addition,
neonatal osteoclasts from mothers exposed to PAM at time-
points PC, E15, and D1 were analyzed to assess osteoclast
number and surface on offspring skeletal development when
exposed to PAM. To assess osteoclast number per bone area
and osteoclast surface percentage, the number and surface of
TRAP‐positive multinucleated cells containing three or more
nuclei was quantified for both mothers and neonates, as well as
the bone surface within the ROI using Bioquant software (Bi-
oquant Image Analysis Corporation, Nashville, TN, USA).
Statistics
Maternal bone architecture data are reported through box
plots where treated (grey) groups are superimposed onto un-
treated (white) groups. Maternal variations in bone archi-
tecture, biomechanics, osteoclasts osteolysis, and osteoclasts
between untreated/treated groups and virgin controls were
determined using a one‐way ANOVA followed by Holm–Sidak
test for multiple comparison. To determine differences be-
tween untreated and treated groups, a two‐way ANOVA was
applied to analyze both maternal and neonatal parameters.
Differences with p values< 0.05 were considered significant. All
statistical analyses were carried out using GraphPad Prism
(version 7.04; GraphPad Software, San Diego, CA, USA). Data are
presented as mean± SD, or by individual values. Box plots,
when presented, display mean (horizontal line), 25th and 75th
percentiles (box), and minima and maxima (bars).
Results
Maternal and neonatal body mass are not affected by
pamidronate treatment
Maternal body mass increased during pregnancy (through E15),
decreased immediately following birth (D1), and increased
again through weaning (D15) (Fig. 2A) in both PAM‐ and PBS‐
treated groups. By the end of lactation (D21), maternal body
mass reached a common value regardless of PAM treatment
status or time of treatment (Fig. 2B). At 21 days of age, the body
mass of genotyped female pups from PBS‐treated dams did not
differ from the body mass of genotyped female pups from
PAM‐treated dams (Fig. 2C). The same observations were seen
in genotyped male pups. Furthermore, consistent with the re-
duced body size in OI, the body mass of heterozygous pups
was significantly lower than the body mass of WT pups in both
females and males. This suggests that neonatal and maternal
body mass was not affected by maternal PAM exposure during
bone formation. The number of sudden deaths of pups in the
litters was evenly distributed between PAM‐treated (n= 9) and
PBS‐treated groups (n= 11), consistent with prior reports of
spontaneous deaths in Brtl/+ pups.(47) In addition, one PAM‐
and two PBS‐treated dams were euthanized because of mor-
bidity prior to the end of the experiment.
Pamidronate effects on pregnancy and
lactation‐induced bone changes are highly dependent
on time of treatment
In Brtl/+ dams, pregnancy alone significantly increased vertebral
Tb.N by 37%, but significantly decreased Tb.Th and TB.Sp, re-
sulting in an overall increase in maternal bone volume fraction of
28% (Fig. 3A, Supplemental Fig. 1; Treatment Timepoint PC; End
Timepoint Birth). The femur was less susceptible to these effects,
as pregnancy had no effect on Tb.N or Tb.Sp, but significantly
decreased Tb.Th (7%), resulting in a 15% net bone loss (Fig. 3B,
Supplemental Fig. 1; Treatment Timepoint PC; End Timepoint
Birth). Conversely, lactation induced a loss in Tb.N in both ver-
tebra (7%) and femur (39%) as seen in Fig. 3A and Fig. 3B
(Treatment Timepoint PC‐D15; End Timepoint Weaning). To-
gether, these changes led to a 13% loss of vertebral bone
volume fraction and an even greater femoral loss of 43% com-
pared with virgin dams. When Brtl/+ dams were treated prior to
conception with PAM, greater gains in vertebral Tb.N were ob-
tained following pregnancy, whereas no significant further gains
were observed in the femur when compared with PBS‐ treated
dams. Strikingly, when dams were carried out to the end of
lactation (weaning of their pups at day 21), PAM induced a
treatment‐induced preservation of bone volume fraction
through retained Tb.N that was directly related to the timing of
injection into both vertebra and femur. A modest preservation of
bone mass was observed in the vertebra when PAM was ad-
ministered prior to conception, whereas significant gains of 58%
were observed in the femur. PAM had no effect on Tb.Th re-
gardless of time of treatment. In the cortical structure, pregnancy
alone did not induce changes in vertebral or femoral C.Th;
however, by weaned date, C.Th was reduced 16% and 10% in
the vertebra and femur, respectively. Despite preservation of
trabecular bone mass during the early stages of pregnancy and
lactation (PC, E15, and D1) with PAM intervention, preservation
of C.Th was only observed when PAM was administered prior to
conception in both the vertebra (Fig. 3C; Treatment Timepoint
PC; End Timepoint Weaning) and the femur (Fig. 3D; Treatment
Timepoint PC; End Timepoint Weaning).
To qualitatively analyze the effects of PAM when ad-
ministered at different stages of pregnancy and lactation,
representative µCT images were extracted from virgin females
and from dams at D21 postweaning to visualize changes in
maternal trabecular and cortical bone morphology. Lactation‐
induced bone loss was observed in both the vertebra and
femur of PBS‐treated dams (Fig. 3E). When PAM was ad-
ministered prior to conception, pregnancy and lactation‐
induced bone loss was completely prevented in Brtl/+ dams
(Fig. 3F). When PAM was administered at E15 during pregnancy
and D1 of lactation, a temporal preservation of bone mass was
observed. No further preservation of trabecular structure was
observed when dams were treated with PAM at D10 and D15 of
lactation, suggesting trabecular bone loss had already occurred
prior to this timepoint.
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PAM‐induced preservation of trabecular and cortical
bone increases stiffness, but not strength during
pregnancy and lactation
Like the response seen in trabecular bone, a temporal effect
was also observed in stiffness for both the vertebra and femur
of PAM‐treated dams. With pregnancy alone, a 57% increase
in vertebral stiffness was observed in PBS‐treated dams
(Fig. 4A), consistent with pregnancy‐induced gains observed
in Tb.N. No stiffness changes were observed in the femur
following pregnancy alone, but a 10% femoral stiffness loss
was observed by the end of lactation (Fig. 4B). When PAM was
administered prior to conception, vertebral stiffness in dams
increased by 151% following pregnancy alone, whereas a 50%
increase was observed when assessed following lactation.
Femoral stiffness assessed at birth and treated prior to con-
ception showed an increase of 15% and an increase of 21%
when assessed following lactation compared with virgin
dams. Treatment with PAM induced a temporal effect on both
vertebral and femoral stiffness when treated with PAM at
different timepoints during pregnancy and lactation similar to
the protective effect observed in their trabecular structure.
Unlike stiffness, ultimate load in the vertebra did not show a
temporal effect with PAM treatment. Instead, when dams
were treated with PAM prior to conception and assessed at
birth, a sustained effect was observed in vertebral max load,
but an overall 26% was noted by weaned date regardless of
PAM timepoint administration. Unlike the vertebra, a temporal
effect with PAM treatment was observed in femoral ultimate
load to failure when assessed at weaning. When dams were
treated with PAM prior to conception, a 6% increase in ulti-
mate load to failure was observed at birth; however, when
assessed at weaning, ultimate load decreased by 10% com-
pared with virgin dams. This protective effect on femoral max
load ceased to exist when PAM was administered at late
stages of lactation. Biomechanical results are summarized in
Fig. 4 and Supplemental Table 1.
Bisphosphonates cross the placenta
To assess if BPs cross the placenta, a fluorescent bi-
sphosphonate imaging agent (Osteosense 680EX) was ad-
ministered when Brtl/+were in late stages of gestation (E19).
As seen in Fig. 5, fluorescent images of the fetal vertebral body
showed localization of BPs during late stages of gestation,
confirming that BPs can cross the placenta.
Neonates at birth and weaning did not show skeletal
adverse effects from maternal pamidronate exposure
Pregnancy and lactation represent a challenging period for the
maternal skeleton as high demands for calcium are required for
Journal of Bone and Mineral Research PAMIDRONATE DURING PREGNANCY AND LACTATION IN MOUSE MODEL OF OI 5 ◼
Fig. 2. Maternal and neonatal body mass are not affected by pamidronate (PAM‐) treatment. (A) Maternal body mass increased as a result of
pregnancy and lactation, and no body mass differences between PBS and pamidronate‐treated groups were observed. (B) Greater gains in maternal
body mass were not induced with PAM treatment. Data are represented for maternal outcomes assessed at birth or weaning for dams treated with
PBS (open box) and PAM (gray box). (C) No differences in body mass of pups from PAM‐treated dams and PBS‐treated dams were observed. Results of
two‐way ANOVA factors: *p< 0.05. HET= heterozygous.
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the healthy development of the neonatal skeleton. Because
pregnancy and lactation‐induced bone loss was prevented in
PAM‐treated dams, assessing neonatal skeletal development
was imperative. At birth, following maternal PAM exposure
during pregnancy alone, neonates (1 day of age) from dams
treated with PAM prior to conception showed no effects from
BP exposure during their early stages of skeletal formation as
no differences in BMD were observed in either the vertebra or
the femur (Fig. 6A). Following maternal PAM exposure during
pregnancy and lactation, at 21 days of age, sexed Brtl/+ and WT
pups from PAM‐treated dams continued to show no effect from
PAM exposure on trabecular and cortical structures (Fig. 6B). To
further assess that PAM exposure during pregnancy and lac-
tation did not induce any adverse effects in the neonate’s
skeletal formation, Safranin O‐stained sections reveal no mor-
phological differences between pups from PBS‐ and PAM‐
treated dams (Supplementary Fig. 2). Thus, despite preventing
pregnancy and lactation‐induced bone loss, no effects were
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Fig. 3. Pamidronate (PAM) effects on pregnancy and lactation‐induced bone changes are highly dependent on time of treatment. µCT data are
represented for virgin controls at baseline (black), followed by maternal outcomes assessed at birth or weaning for dams treated with PBS (open box)
and PAM (gray box). Bone microstructural analysis of the maternal Brtl/+ skeleton showed a temporal response to PAM intervention during
pregnancy and lactation in both vertebra (A) and femur (B). A less robust temporal effect was observed in maternal cortical bone of both vertebra (C)
and femur (D). Representative µCT isosurfaces of the distal femur metaphysis and the vertebral body reflect maternal bone structure in response to
pregnancy and lactation in both untreated (E) and treated dams (F). Results of one‐way ANOVA factors: PAM and (PBS) compared with virgin
controls:++++p< 0.00005,+++p< 0.0005,++p< 0.005, and+p< 0.05. Results of two‐way ANOVA factors: ****p< 0.00005, ***p< 0.0005,
**p< 0.005, and *p< 0.05. PC= prior to conception; HET= heterozygous.
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observed in pups from PAM‐treated dams compared with pups
from PBS‐treated dams.
Pamidronate increases maternal osteoclast number and
surface, but has no effect on neonates exposed to
pamidronate during the early stage of skeletal formation
and lactation
To examine the presence of osteoclasts following maternal PAM
exposure during pregnancy and lactation, mature osteoclasts
positive for TRAP staining were identified in maternal tibia for all
groups carried out through the end of lactation. TRAP+mature
osteoclasts (Fig. 7A; N.Oc/BS) were present in both PAM‐
and PBS‐treated dams, albeit statistically more in PAM‐treated
Brtl/+ dams. However, no differences were observed in osteoclast‐
surface coverage (Fig. 7A; Oc.S/BS) between PAM‐ and PBS‐treated
dams. To further assess the effect of the potential exposure to
PAM during skeletal development, osteoclast number and surface
in day 21 neonates from PBS‐ and PAM‐treated dams were also
analyzed following maternal intervention at prior to conception,
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Fig. 4. Pamidronate‐ (PAM‐) induced preservation of trabecular and cortical bone increases stiffness, but not strength during pregnancy and
lactation. Data for biomechanical properties are represented for virgin controls at baseline (black), followed by maternal outcomes assessed at birth or
weaning for dams treated with PBS (open box) and PAM (gray box). (A) With PAM treatment prior to conception, significant gains in vertebral stiffness
were observed following pregnancy and lactation, but no preservation in maximum load to fracture was observed. Similarly, in the femur, PAM
showed a sustained effect on stiffness and also a loss in maximum load to fracture (B). Results of one‐way ANOVA factors: PAM and (PBS) compared
with virgin controls:++++p< 0.00005,+++p< 0.0005,++p< 0.005, and+p< 0.05. Results of two‐way ANOVA factors: ****p< 0.00005,
***p< 0.0005, **p< 0.005, and *p< 0.05. PC= prior to conception.
Fig. 5. Bisphosphonates (BPs) cross the placenta. Fluorescent nontherapeutic BPs localized in fetal vertebral body during late stages of gestation.
Control tissues from animals receiving PBS and imaged under identical acquisition settings show negative fluorescence.
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E15 and D1. No differences in osteoclast number and surface
coverage (Fig. 7B) between neonates from PAM‐ and PBS‐treated
dams were observed, suggesting that either our PAM dosage
provides a low‐exposure risk during crucial periods of skeletal
development or that PAM has not yet taken an effect on
neonatal bone.
Pamidronate did not further increase osteocyte lacunar
area during pregnancy
Backscattering imaging was used to analyze PAM effects on ma-
ternal osteocyte osteolysis during pregnancy and lactation at
standard locations of the femoral cortical bone (Fig. 8A). Con-
sistent with other studies, a significant increase in osteocyte os-
teolysis was observed following pregnancy in PBS‐treated dams
(Fig. 8B). A similar increase was observed when dams were treated
with PAM, suggesting that PAM intervention had no effect on
lacunar size. By the end of lactation, when calcium demand is low,
osteocyte osteolysis decreased and PAM continued to show no
effect. Representative images of the differences in lacunar area
under these conditions are shown in Fig. 8C.
Discussion
The present study shows that pregnancy led to maternal gains
in vertebral trabecular bone mass observed at parturition,
whereas lactation induced maternal cortical and trabecular
bone loss in both vertebra and femur observed at weaning in
Brtl/+mice harboring an OI‐inducing Gly‐ > Cys mutation in
col1a1. PAM intervention led to a temporal retention of ma-
ternal cortical and trabecular bone in both vertebra and femur.
When PAM was administered PC, bone mass gains caused by
pregnancy were amplified and lactation‐induced bone loss was
prevented. This protective effect was more modest when given
during pregnancy (E15) and ceased to exist in the late stages of
lactation (D10 and D15). Furthermore, pregnancy induced os-
teocyte osteolysis, which was unaffected by PAM treatment.
Despite preventing lactation‐induced maternal bone loss, no
negative skeletal effects from PAM exposure on offspring were
observed. Because the use of BPs is increasing in pre-
menopausal women with diseases of high bone remodeling
rates like OI, these findings provide important clinical insight
into a window for when PAM is most effective in preserving
maternal bone mass and how maternal exposure may affect
embryonic and neonatal skeletal development.
Current knowledge on the effect of BPs during pregnancy
remains limited and is based almost entirely on animal toxicity
studies that show transplacental effects of BPs.(30–33) Many of
the adverse effects noted in these studies are likely dose‐
related; however, fewer studies exist that examine subtoxic
doses. No adverse maternal or offspring effects were observed
in a rat and rabbit study using low dosages of incadronate;
however, when dosage was increased, dam death, retarded
fetal ossification, and abnormal tooth growth were noted.(33)
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Fig. 6. Neonates at birth and weaning did not show skeletal adverse effects from maternal pamidronate exposure. (A) No changes in vertebral and
femoral bone mineral density were observed at birth in sexed Brtl/+ and WT offspring following PAM exposure during the embryonic stage. (B) At 21
days of age, sexed Brtl/+ and WT neonates from PBS‐ and pamidronate‐ (PAM‐) treated dams showed no change in bone mass or cortical thickness
when exposed to PAM at different stages of their skeletal development. Results of two‐way ANOVA factors: ****p< 0.00005, ***p< 0.0005,
**p< 0.005, and *p< 0.05. PC= prior to conception; HET= heterozygous.
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Human data on BP effects during pregnancy are also limited.
Scattered clinical cases reported uneventful pregnancies under
BP treatment,(19,44,61) but a few case studies did show low birth
mass corresponding to lower gestational age, as well as an
increased incidence of spontaneous abortions.(62) However,
based on the rarity of these outcomes, these effects may have
arisen from underlying conditions affecting the mother rather
than BP itself.
To date, two animal toxicity studies have explored the effects
of BPs during lactation. Both bovine and rat studies showed
that EHDP and Cl2MBP, respectively, induce hypocalcemia in
response to the inhibition of lactation‐induced bone loss.(34,35)
Several other animal studies have shown evidence of post-
lactation recovery of maternal bone loss,(63–65) which may occur
independent of preceding resorption events. When zoledro-
nate was administered to mice at the beginning of lactation,
bone formation persisted after forced weaning despite pre-
vention of lactation‐induced bone loss.(66) With regards to
human data, there is a dearth of case studies reporting the
effects of BPs when administered prior to or during lactation. Of
the human case studies that are available, both mother and
infant did not demonstrate serious adverse effects(39,41,62,67);
however, one report cited an OI mother, with a year history of
alendronate and PAM, gave birth to a asymptomatic hypo-
calcemic newborn.(38)
The present study differs from prior animal studies by using a
single clinical dose compared with the high doses previously
used to evaluate BP safety during pregnancy and lactation. We
observed that pregnancy triggered a significant increase in
trabecular bone volume fraction of Brtl/+ dams, similar to re-
sults observed in other animal studies.(68,69) However, this in-
crease in bone mass was only observed in the vertebral body;
no significant differences were noted in the distal femur.
During pregnancy, studies have shown that there is an accu-
mulation of calcium in the maternal skeleton to serve as a
calcium reservoir during lactation.(70) Other animal studies have
also reported that following conception, there is a rapid gain of
skeletal mass and its utilization begins around late pregnancy
when the fetal skeleton starts to form and develop.(71,72) This
process is then followed by a decline in maternal bone mass
during lactation, as the neonatal skeleton begins to miner-
alize.(73,74) Similar findings were observed in the present study,
as trabecular bone mass significantly decreased in both the
vertebra and distal femur during lactation. Although other
studies report greater changes in the vertebra,(75) our results
showed greater lactation‐induced bone loss in the distal femur.
This may be because of the timing of neonatal weaning, as
other studies report lactation results following forced weaning
(12 days of lactation). In our study, mice were weaned naturally
on day 21, which may have led to some percentage of bone to
be recovered by day 21 as the lactation demand is reduced as
neonates transition to chow. However, these lumbar results
corroborate with other studies that show a significant decrease
in trabecular thickness and not number in the vertebra fol-
lowing lactation.(66,75) Although pregnancy did not induce any
response on cortical bone, significant thinning of the cortical
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Fig. 7. Pamidronate (PAM) increases maternal osteoclast number and surface, but has no effect on neonates exposed to PAM during the early stage
of skeletal formation and lactation. Maternal osteoclast number/surface data are represented for virgin controls at baseline (black), followed by
maternal outcomes assessed at birth or weaning for dams treated with PBS (open box) and PAM (gray box). (A) Histomorphometric quantification of
TRAP‐stained tibial bone sections showed that PAM treatment increased maternal osteoclast number and surface coverage compared with PBS‐
treated dams. No temporal effect was observed with PAM treatment. (B) Osteoclasts number and surface in pups from PAM‐treated dams was not
significantly altered with PAM exposure at PC, E15, and D1 compared with pups from PBS‐treated dams. Results of one‐way ANOVA factors: PAM and
(PBS) compared with virgin controls:++++p< 0.00005,+++p< 0.0005,++p< 0.005, and+p< 0.05. Results of two‐way ANOVA factors:
****p< 0.00005, ***p< 0.0005, **p< 0.005, and *p< 0.05. PC= prior to conception; HET= heterozygous.
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bone was observed following lactation, consistent with results
reported in other studies.(70,73,77)
Because we confirmed through FRFP that BPs cross the
placenta and that PAM intervention prevented lactation‐
induced bone loss in maternal bone, it was vital to assess if fetal
and neonatal bone development was affected as well.
Surprisingly, vertebral and femoral BMD of newborn WT and
Brtl/+mice (1 day of age) was unchanged when BP was
administered to mothers prior to conception or during the
embryonic stage. We propose four possible pathways of neo-
natal exposure that occurs when dams are treated with PAM
during different stages of pregnancy and lactation as shown in
Fig. 9: (1) Treatment with PAM PC, or BP recycling resulting
from bone resorption during high periods of high calcium
demand, might expose offspring during both the embryonic
stage (placental crossing) or neonatal stage (lactation and
breast milk) prior to weaning. (2) Treatment with PAM during
gestation may lead BP in the bloodstream to potentially cross
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Fig. 8. Pamidronate (PAM) did not further increase the osteocyte lacunar area during pregnancy. (A) Panels show the location of measurements and
representative images of lacunae from PBS‐ and PAM‐treated dams. (B) Pregnancy‐induced osteocytic lacunar enlargement in the femur as measured
by backscatter electron microscopy. By the end of lactation, the osteocyte lacunar area remodeled back to baseline. Lacunar data are represented for
virgin controls at baseline (black), followed by maternal outcomes assessed at birth or weaning for dams treated with PBS (open box) and PAM (gray
box). (C) Representative SEM backscatter panels of cortical bone for virgin dams, and dams after pregnancy or lactation. Results of one‐way ANOVA
factors: PAM and (PBS) compared with virgin controls:++++p< 0.00005,+++p< 0.0005,++p< 0.005, and+p< 0.05. Results of two‐way ANOVA
factors: ****p< 0.00005, ***p< 0.0005, **p< 0.005, and *p< 0.05. PC= prior to conception.
Fig. 9. Assessing pamidronate (PAM) effects on offspring bone on offspring bone development from PAM exposure. Proposed pathways of PAM
exposure on fetal and skeleton bone development when the maternal skeleton is treated with bisphosphonates during the different stages of
pregnancy and lactation. Not shown, potential indirect effect on calcium homeostasis from osteoclastic inhibition of maternal bone resorption during
fetal and neonatal bone development. PC= prior to conception.
Journal of Bone and i r ln 2070 OLVERA ET AL.
the placenta, exposing the embryo to PAM (E15). (3) PAM
treatment during lactation may lead to diffusion of BPs into
breast milk, exposing neonates to PAM during a time they
highly depend on their mothers for survival (D1). (4) Lastly,
PAM can indirectly interfere with fetal and neonatal develop-
ment by inhibiting maternal bone resorption. This in return can
disrupt calcium homeostasis and prevent offspring from re-
ceiving the necessary calcium supply for healthy bone devel-
opment. Embryonic bone ossification has been reported to
start near gestation day 14.(78) Therefore, administration of PAM
to mothers during early stages of fetal bone ossification may
lead to BP exposure to the offspring through placental crossing
and localization on mineralized fetal bone during the embry-
onic stage. During lactation, it has also been well‐established
that the demand for calcium is greatest when the offspring is
solely dependent on the mother for nourishment and de-
creases as offspring are introduced to outside food
sources.(63,79) As a result, when the maternal skeleton was
treated with PAM at D1, D10, or D15 of lactation, the risk of
exposure through diffusion into the breast milk was likely
greatest at the beginning of lactation. Because of the long half‐
life of BPs, treating dams prior to conception may expose fetal
and neonatal bone to PAM through bisphosphonate recycling
secondary to maternal bone resorption. Alternatively, PAM can
indirectly interfere with fetal and neonatal skeletal develop-
ment secondary to inhibition of maternal bone resorption. Di-
rect disruption of maternal calcium homeostasis through
antiresorptive effects may prevent offspring from receiving the
necessary calcium supply for healthy bone development. De-
spite these potential exposures to PAM, Brtl/+ and WT off-
spring (21 days of age) from treated and untreated mothers
showed no differences in trabecular bone mass or cortical
thickness. These findings suggest that the single PAM exposure
had no effect on skeletal development whether potentially
transferred through the placenta, breast milk, or BP recycling
resulting from maternal bone resorption, or through altered
maternal calcium homeostasis.
We observed no difference in osteoclast surface or number in
maternal tibias between virgin controls and PBS‐treated dams
following lactation, despite the trabecular bone loss observed
during this time. It is possible that we missed the window of
high osteoclast number/surface because assessment was per-
formed at time of weaning when bone turnover rate has
slowed down (as seen from our D10 and D15 treated dams);
however, no osteoclast assessment was performed following
parturition. To support these findings, there is accumulating
evidence that the conclusion of lactation is associated with
maternal metabolic changes to reverse bone loss and increase
bone formation to recover the maternal skeleton and rebuild its
mineral storage in preparation for the next reproductive pe-
riod.(80) In fact, female mice are in fertile estrus about 10 and
24 hours after giving birth, suggesting that this window of re-
covery is particularly short in mice. Furthermore, osteoclasts
become apoptotic immediately with the cessation of lacta-
tion.(81) Similarly, we did not observe an effect of PAM on os-
teoclast surface coverage, but greater osteoclast numbers were
observed with treatment. The literature on the effect BPs have
on osteoclast number remains mixed. In rats treated with a
high dose of zoledronate, the number of osteoclasts increased
significantly, and a number of other studies have shown that
the number of osteoclasts could be unaffected or even become
elevated during BP treatment.(82–84) Alternatively, another
study showed that treatment with zoledronic acid reduced
osteoclast surface when administered for both short and long
durations.(85)
We assessed osteoclast number and surface in the neonates
at wean date because it would allow us to evaluate the po-
tential risk of PAM exposure on the role of osteoclasts during
the ossification and mineralization stages of bone develop-
ment. We explored timepoints PC, E15, and D1 because not
only was maternal bone loss inhibited with PAM at these
timepoints, but these timepoints dictate three possible routes
of fetal and neonatal BP exposure. Considering that no differ-
ences on osteoclast surface and number were observed, we can
conclude that in this model, BP exposure through recycling
(PC), placental crossing (E15), and diffusion into breast milk (D1)
have no effect on embryonic and neonatal development. These
limited effects might be because of two possibilities: (1) The
embryonic and neonatal bone formation rate may exceed bone
resorption, so osteoclasts do not play a significant role during
these early stages of bone development; or (2) a single PAM
dosage to the mother was not enough to induce a significant
biological effect in the offspring.
Although osteoclasts have been assumed to be primarily
responsible for the removal of bone during calcium homeo-
stasis, osteocytes have also been found to play a role during
periods of increased calcium demand. Although some studies
have shown osteocytes play a role in calcium homeostasis
during pregnancy and lactation,(59,86) others have not.(87) In our
study, following pregnancy, Brtl/+ dams showed an increase in
the lacunar area, which returned to baseline by the end of
lactation. Although these changes were modest (16%), it is
possible that the lacunar area was higher during the earlier
stages of lactation. Prior studies have shown osteocytic peril-
acunar and canalicular remodeling on the 12th(58) and 14th day
of lactation,(88) though our observations were limited to par-
turition and weaning only. Most importantly, although ma-
ternal bone loss was prevented with PAM intervention, PAM
showed no effect on osteocyte lacunar remodeling during this
crucial period of calcium demand. Conversely, others have
shown inhibition of osteocyte osteolysis during lactation
through calcitonin(89) and parathyroid hormone,(90) which may
reflect a direct action on the osteocytes through related sig-
naling pathways.
This study has several limitations. To assess the effect of a
history of BP therapy, a single PAM dosage was administered
prior to conception, which does not reflect continuous BP ac-
cumulation in the maternal skeleton arising from extensive
treatment prior to conception in humans. Exploring a wider
range of dosages will be important to assess the full effects of
bone interventions during pregnancy and lactation. It is well‐
established that BPs have a long half‐life and remain em-
bedded in the bone matrix until liberated during osteoclastic
resorption. Thus, fetal and neonatal BP effects might not be
observed until later stages of rapid growth or adulthood when
BPs are recycled through bone remodeling. Therefore, although
no effects were observed on weaned pups, BP exposure risk
should not be disregarded, and postlactation assessment of
neonatal growth should be considered. Despite inhibiting lac-
tation‐induced decrease in maternal bone mass, no effects
were observed in fetal and neonatal bone development.
However, we did not analyze calcium levels in mothers or their
offspring to verify that PAM did not indirectly interfere with
fetal and neonatal development secondary to inhibition of
maternal bone resorption. Additionally, we did not biochemi-
cally analyze maternal milk to assess neonatal PAM exposure
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during lactation. Though studies have established that preg-
nancy upregulates intestinal calcium absorption,(91) we did not
monitor whether an increase in intestinal calcium absorption is
observed when lactation‐induced bone loss is prevented with
BP treatment. The present study assessed the effects of preg-
nancy and lactation‐induced bone loss and the effects fol-
lowing PAM intervention using only Brtl/+mice. Because no
WT controls were analyzed, we cannot conclusively determine
whether the skeletal findings in this study are dependent on OI
or specific to the background strain of the mice. Although other
studies have shown an increase in osteoclastic bone resorption
during lactation, our lack of similar observations in this study is
likely based on our postweaning timing when bone mass is
already recovering.
Aside from studying the effects of bone therapeutics in
animal models for their translation into human clinical trials,
studying any therapeutic effect during pregnancy and lacta-
tion raises several challenges particularly because mice have
a shorter gestation period (18 to 21 days) than humans
(280 days). In this study, PAM was administered in mice on
gestation day 15, which has been shown to approximate week
8 of pregnancy in humans.(92) Although this timepoint rep-
resents the commencement of ossification in both time-
lines,(92,93) the rapid skeletal development in mice significantly
reduces their risk of possible transplacental exposures. As a
result, PAM intervention in humans might lead to greater
exposure risks in utero because 80% of their gestation period
remains as opposed to 29% in mice. Once born, there is a wide
variation in the developmental phases between mice and
humans and correlating their relative ages can be determined
through several factors.(94) For example, mice are weaned at
day 21 postbirth, whereas on average the weaning age for
humans is about 6 months (180 days).(95) Thus, in this study,
neonatal mice were exposed to PAM on days 1, 10, and 15 of
lactation, which approximate 9, 86, and 129 days of age in
humans, respectively. However, this correlation through
weaned date may not accurately represent the metabolic
bone state between both timelines, suggesting that further
studies are necessary.
During pregnancy and lactation, significant demands are
placed on the maternal skeleton to provide the necessary cal-
cium supply required for fetal and neonatal bone formation. The
changes in calcium homeostasis during these reproductive pe-
riods can influence a time‐dependent BP effect on bone me-
tabolism that is not captured in toxicology studies. The results in
this study capture the temporal effects on bone metabolism
when PAM was administered at different stages of pregnancy
and lactation. Specifically, when the maternal skeleton was
treated with PAM prior to conception, lactation‐induced bone
loss was prevented. Despite inhibiting lactation‐induced bone
loss with PAM treatment, no adverse effects were observed on
neonatal bone development. Additionally, our results of osteo-
cyte remodeling provided further insight to their contribution to
the regulation of calcium homeostasis during periods of high
calcium demand from the maternal skeleton. In this study, cal-
cium release from trabecular thinning and osteocyte osteolysis
during pregnancy and potentially intestinal absorption (though
not tested here) may have contributed to the healthy neonatal
bone development observed. These results offer a treatment
window during pregnancy and lactation for when PAM is most
effective and offer further significant insight into the maternal
changes in bone metabolism caused by calcium homeostasis
during this reproductive period.
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